AIDS Deaths Fall by 19% in United States

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 8
Volume 6
Issue 8

WASHINGTON--The number of deaths from AIDS has fallen 19%, from 37,900 in the first nine months of 1995 to 30,700 for the same time period in 1996, the Centers for Disease Control and Prevention (CDC) has announced. And, for the first time, the number of AIDS-related deaths has dropped among women, albeit by only 7%, as compared to 22% among men.

WASHINGTON--The number of deaths from AIDS has fallen 19%, from 37,900in the first nine months of 1995 to 30,700 for the same time period in1996, the Centers for Disease Control and Prevention (CDC) has announced.And, for the first time, the number of AIDS-related deaths has droppedamong women, albeit by only 7%, as compared to 22% among men.

The heartening news appears to be due primarily to new drug therapiesdeveloped to combat the virus and to treat AIDS-related complications,as well as improved access to medical care.

The greatest decrease was among white patients (28%), compared with16% for Hispanics and 10% for blacks.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content